Table 1.
General characteristics of the cohort.
| n = 133 | |||
|---|---|---|---|
| Sex | Female | 53 (39.85%) | |
| Male | 80 (60.15%) | ||
| Area | Rural | 59 (44.36%) | |
| Urban | 74 (55.64%) | ||
| Age (years) | 5 (2, 10) | ||
| Age groups | 1–6 years | 80 (60.2%) | |
| 7–10 years | 22 (16.5%) | ||
| 11–17 years | 31 (23.3%) | ||
| Leukocytes × 109/L | 11.1 (4.92, 32.77) | ||
| Leukocyte groups | <10 × 109/L | 61 (45.9) | |
| 10–20 × 109/L | 21 (15.8) | ||
| 20–50 × 109/L | 25 (18.8) | ||
| >50 × 109/L | 26 (19.5) | ||
| Hemoglobin (g/dL) | 8.74 +/– 2.4 | ||
| Hemoglobin groups | <7 g/dL | 30 (22.56%) | |
| 7–10 g/dL | 71 (53.38%) | ||
| >10 g/dL | 32 (24.06%) | ||
| Platelets × 109/L | 51 (29, 112) | ||
| Platelet groups | <20 × 109/L | 15 (11.28%) | |
| 20–50 × 109/L | 49 (36.84%) | ||
| 50–100 × 109/L | 32 (24.06%) | ||
| >100 × 109/L | 37 (27.81%) | ||
| Morphology | L1 | 129 (97%) | |
| L2 | 4 (3%) | ||
| Immunophenotype | B | proB | 2 (1.5%) |
| B common | 84 (63.16%) | ||
| preB | 25 (18.79%) | ||
| T | 22 (16.54%) | ||
| Cytogenetics | No evaluable metaphases | 40 (30%) | |
| Normal karyotype | 46 (34.6%) | ||
| Abnormalities | 47 (35.4%) | ||
| Molecular biology | None | 94 (70.8%) | |
| TEL-AML1/ETV6-RUNX1 | 24 (18%) | ||
| E2A-PBX1/ TCF3-PBX1 | 4 (3%) | ||
| MLL-AF4/ KMT2A-AFF1 | 4 (3%) | ||
| BCR-ABL1 p190 | 4 (3%) | ||
| BCR-ABL1 p210 | 2 (1.5%) | ||
| SIL-TAL1 | 1 (0.7%) | ||
| CNS involvement | 1 (0.75%) | ||
| Prednisone response | Good | 115 (86.47%) | |
| Poor | 18 (13.53%) | ||
| Risk group | High | 44 (35.2%) | |
| Intermediate | 61 (48.8%) | ||
| Standard | 20 (16%) | ||
| Day 15 bone marrow morphologic disease | M1 | 53 (59.55%) | |
| M2 | 27 (21.6%) | ||
| M3 | 9 (7.2%) | ||
| Day 33 bone marrow morphologic disease | M1 | 109 (99.09%) | |
| M2 | 0 (0%) | ||
| M3 | 1 (0.9%) | ||
| Day 15 FCM-MRD groups | <0.1% | 29 (25.44%) | |
| 0.1–1% | 23 (20.18%) | ||
| 1–10% | 39 (34.21%) | ||
| >10% | 23 (20.18%) | ||
| Day 33 FCM-MRD groups | <0.05% | 94 (83.93%) | |
| >0.05% | 18 (16.07%) | ||
| Day 78 MRD | Positive (>0.01%) | 0 (0%) | |
| Negative (≤0.01%) | 103 (100%) | ||